Melanotan-2 (MT-II)

Melanotan II emerged from University of Arizona research in the 1980s on synthetic analogs of alpha-melanocyte-stimulating hormone. Natural α-MSH is rapidly degraded, so investigators developed shorter cyclic analogs intended to increase stability and melanocortin-receptor activity. By the mid-1990s, a Phase 1 study had evaluated Melanotan II for pigmentation. Participants developed visible tanning, while nausea, yawning and somnolence were among the reported effects.¹ An unexpected observation—erectile responses—shifted part of the research program toward central melanocortin pathways and sexual function. A controlled study in men followed in 1998.² Animal and human research subsequently linked these effects to central melanocortin signaling.³ ⁴ The findings also contributed to development of related compounds, including PT-141, or bremelanotide.⁵–⁷ Melanotan II therefore has a research history spanning pigmentation and neurobehavioral melanocortin signaling. It remains a broad, nonselective melanocortin agonist and has not been approved by the FDA or EMA for tanning, cosmetic use or therapeutic use.

Melanotan II is a broad melanocortin-receptor agonist whose effects vary with the receptor subtype and tissue involved. In melanocytes, MC1R activation stimulates melanogenic signaling and increases production of eumelanin, the darker form of melanin.⁸ This pathway explains the pigmentation response observed in early human research; it does not establish complete protection from ultraviolet injury. Melanotan II also activates melanocortin receptors in the central nervous system. MC3R and MC4R participate in neural networks that regulate feeding behavior, energy balance and autonomic output.⁹ Because Melanotan II is not selective for MC4R, observed appetite-related effects cannot be assigned to one receptor without qualification. Central MC4R-related signaling is also associated with sexual arousal and erectile responses. Controlled human research reported erectile effects, helping motivate development of more selective melanocortin compounds.¹⁰ Activity at additional subtypes, including MC5R, may contribute peripheral effects, but these pathways are less clearly characterized. Its multi-receptor pharmacology explains the range of experimental observations and also makes off-target effects more likely than with a subtype-selective agonist.